CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma

Lancet Haematol. 2023 Dec;10(12):e951-e952. doi: 10.1016/S2352-3026(23)00335-6.

¹ Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Electronic address: [email protected].
² Department of Hematology, University Hospital of Düsseldorf and Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Düsseldorf, Germany. Electronic address: [email protected].
³ Department of Hematology, University Hospital of Düsseldorf and Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Düsseldorf, Germany.

No abstract available

MeSH terms